2018
DOI: 10.2147/btt.s140114
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Oncolytic viruses have demonstrated selective replication and killing of tumor cells. Different types of oncolytic viruses – adenoviruses, alphaviruses, herpes simplex viruses, Newcastle disease viruses, rhabdoviruses, Coxsackie viruses, and vaccinia viruses – have been applied as either naturally occurring or engineered vectors. Numerous studies in animal-tumor models have demonstrated substantial tumor regression and prolonged survival rates. Moreover, clinical trials have confirmed good safety profiles and … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
22
0
3

Year Published

2018
2018
2020
2020

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 29 publications
(25 citation statements)
references
References 178 publications
(214 reference statements)
0
22
0
3
Order By: Relevance
“…In patients with RB status, the response was higher than 80%, whereas in those receiving six weekly doses, the response was 70%. However, phase 2/3 trials are underway for its complete evaluation ( 141 , 142 , 144 ). Correspondingly sipuleucel-T is the first FDA-licensed cellular immune therapy vaccine against non-viral cancer ( 145 ).…”
Section: Vaccine-based Immunostimulatory Approaches Toward Cancermentioning
confidence: 99%
“…In patients with RB status, the response was higher than 80%, whereas in those receiving six weekly doses, the response was 70%. However, phase 2/3 trials are underway for its complete evaluation ( 141 , 142 , 144 ). Correspondingly sipuleucel-T is the first FDA-licensed cellular immune therapy vaccine against non-viral cancer ( 145 ).…”
Section: Vaccine-based Immunostimulatory Approaches Toward Cancermentioning
confidence: 99%
“…The second approach involves attenuating the pathogenicity of oncolytic viruses to normal cells by genetic modification of the viruses, many of which have been used in studies. To develop oncolytic HSV-1 drugs, such as T-VEC and G207, the ICP-34.5 gene in HSV1716, which is a neurovirulence factor of HSV, was deleted, attenuating the infectivity of HSV in normal neurons (73,117,122,124,125). Mutation and deletion of the E1 gene can reduce adenovirus selectivity of normal cells, and this genetic modification was made to the Onyx-015 and H10 viruses (90,126).…”
Section: Methods To Improve the Biosafety Of Oncolytic Virotherapymentioning
confidence: 99%
“…Whether it is safe for these patients to be administered oncolytic virotherapy is debated (73). Children with severe combined immunodeficiency (SCID) who received an oncolytic retrovirus were found to have viral genes integrated into the LMO2 proto-oncogene region, which triggered the development of leukemia, reducing the survival rate of these patients with this compromised condition (122).…”
Section: Potential Biosafety Issues Of Oncolytic Virotherapiesmentioning
confidence: 99%
“…). 현재 세계적으로 다수의 암용해바이러스 치료제 후보 가 종양모델 실험동물과 인간을 대상으로 임상시험이 진 행되고 있어서, 앞으로 새로운 암용해바이러스 치료제가 등장할 것으로 예상된다(Lundstrom, 2018). 본 연구는 종양 의 치료에서 암용해바이러스의 중요성이 커져 감에 따라 치료제 등이 포함된다(Kwon, 2017).최근 10여년 동안 항암제의 개발은 주로 인간의 면역반 응에 기반을 둔 면역항암치료제가 주류를 이루고 있다.…”
unclassified